News and Announcements
Latest Investment Opportunity from ISG Funds Management
- Published November 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
16 Month Healthcare Property Development Fund, Projected Return 28%
General overview only – does not constitute an offer document.
- Development of prominent Gold Coast Health Care Facility
- 100% tenanted
- Offer available to Wholesale Investor members only
- For further details and offer document click request offer below.
About ISG Funds Management
ISG is a specialised funds manager, whose board and directors collectively have over $4.3 billion in property funding experience, and have managed funds in excess of $1.3 billion. The ISG Group have historically returned investors a minimum of 20% per annum net of fees since February 2014 through its wholesale property development funds (1).
(1) Past returns calculated from projects completed by ISG Group under a wholesale fund and different licensing structure. Returns are not guaranteed. Past performance does not guarantee future performance. Performance is net of fees and annualised, without distributions re-invested. Calculations are based on exit price after ongoing fees and expenses, but excluding individual tax. Returns are not calculated from current ISG Managed Investment Structure and licensing.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
